Table of Contents
- What is ‘Workflow Agent Fit’ and is it the secret to the first billion-dollar Soloicorn?
- Key Takeaways
- Matthew Gallagher runs a projected $1.8 billion company from a kitchen table with exactly one employee
- Don’t buy the “Soloicorn” hype without checking the receipt, though
- The operation also plays a high-stakes game of regulatory arbitrage
- The financials are staggering
What is ‘Workflow Agent Fit’ and is it the secret to the first billion-dollar Soloicorn?
Discover how Medvi reached a projected $1.8B revenue run rate with just two employees. Learn how they used AI to collapse the “administrative lattice,” mastered “Workflow Agent Fit,” and whether this Soloicorn model is the future of the firm or a regulatory mirage.
Key Takeaways
What: Medvi is a two-person telehealth startup reaching a projected $1.8 billion revenue run rate.
Why: It uses AI to collapse the “administrative lattice,” achieving 16.2% net margins—triple those of legacy competitors.
How: By automating workflows through AI agents and “renting” third-party medical infrastructure as compliance endpoints.
Matthew Gallagher runs a projected $1.8 billion company from a kitchen table with exactly one employee
his brother. Medvi isn’t just a lean startup; it’s a structural wrecking ball aimed at the traditional Theory of the Firm. Gallagher severed the link between headcount and growth by collapsing the “administrative lattice”—the messy web of middle managers and status meetings that typically kills a company’s speed.
Most corporate legacy players operate like a 10-lane US highway during rush hour—every handoff between departments is a bottleneck where data and time grind to a halt. Medvi bypassed the traffic. Instead of human nodes sending Slack messages, Gallagher built a direct nervous system where APIs and AI agents talk to each other in milliseconds. He calls this “Workflow Agent Fit”. He doesn’t hire VPs; he chains together lead gen, medical intake, and pharmacy routing into an automated loop that replaces an entire corporate office.
Don’t buy the “Soloicorn” hype without checking the receipt, though
Critics on Hacker News rightly point out that Medvi is a reseller mirage. It isn’t a pure AI company; it’s a high-speed interface for human-heavy services. Gallagher didn’t build a doctor network or a pharmacy; he rents them through platforms like CareValidate and OpenLoop Health. He treats licensed physicians as “compliance endpoints”—essentially physical-world API calls that satisfy a legal checkbox so he can ship compounded GLP-1 drugs.
The operation also plays a high-stakes game of regulatory arbitrage
Gallagher pushes legal liability to the practitioners at the end of the line, while his AI customer service bots have been known to hallucinate drug prices and product lines. Early versions of the site even featured AI-generated “before-and-after” photos and fake media logos. To fix the “AI slop” without hiring a Quality Control team, he uses “algorithmic redundancy”—a three-computer flight setup where independent agent clusters monitor and outvote each other’s errors.
The financials are staggering
Medvi generated $401 million in 2025 with a 16.2% net profit margin, dwarfing the 5.5% margin of Hims & Hers, a competitor with over 2,400 employees. However, the FDA is already circling with warning letters about marketing claims and the legality of compounded drugs. If regulators eventually mandate a human circuit breaker at the orchestration layer, Gallagher’s two-man show will need a massive compliance apparatus overnight. For now, he’s proving that when coordination costs hit zero, the only moat left is how fast you can navigate legal gray areas before the rules catch up. It’s a future that’s incredibly efficient, highly profitable, and—as Gallagher himself admits—a little bit lonely.